Janiczek Wealth Management’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
$328K Buy
606
+72
+13% +$38.1K 0.07% 116
2024
Q1
$277K Sell
534
-2
-0.4% -$995 0.06% 141
2023
Q4
$253K Buy
536
+94
+21% +$43.5K 0.06% 128
2023
Q3
$192K Buy
442
+79
+22% +$35.8K 0.05% 147
2023
Q2
$161K Buy
363
+86
+31% +$39.7K 0.04% 157
2023
Q1
$134K Sell
277
-69
-20% -$32.8K 0.04% 167
2022
Q4
$165K Buy
346
+51
+17% +$25.9K 0.05% 146
2022
Q3
$138K Buy
295
+105
+55% +$50.2K 0.05% 146
2022
Q2
$91K Hold
190
0.03% 216
2022
Q1
$93K Buy
190
+17
+10% +$7.77K 0.03% 216
2021
Q4
$80K Buy
173
+78
+82% +$32.8K 0.02% 222
2021
Q3
$35K Buy
95
+50
+111% +$19K 0.01% 347
2021
Q2
$17K Hold
45
0.01% 460
2021
Q1
$16K Sell
45
-226
-83% -$72.7K 0.01% 444
2020
Q4
$87K Buy
271
+239
+747% +$73.3K 0.04% 126
2020
Q3
$9K Buy
+32
New +$8.61K ﹤0.01% 251
2018
Q3
Sell
-11
Closed -$3K 154
2018
Q2
$3K Buy
+11
New +$2.55K ﹤0.01% 120

Other funds holding ELV

Janiczek Wealth Management's ELV Position: Q2 2024 in Review

Janiczek Wealth Management increased its Elevance Health (ELV) stake by 13% in Q2 2024, buying an estimated $38.1K and bringing the position to 606 shares worth $328K. The position accounts for 0.07% of the portfolio, ranked #116.

Janiczek Wealth Management first reported a position in ELV in Q2 2018 and has held it in 17 quarters since. 1,705 funds tracked by Wall St. Rank hold ELV as of Q2 2024.

  • Janiczek Wealth Management held 606 shares of Elevance Health worth $328K as of Q2 2024.
  • Janiczek Wealth Management bought 72 Elevance Health shares in Q2 2024, an estimated $38.1K.
  • Elevance Health made up 0.07% of Janiczek Wealth Management's portfolio in Q2 2024, its #116 holding.
  • Janiczek Wealth Management first reported a position in Elevance Health in Q2 2018 and has held it in 17 quarters since.
  • 1,705 funds tracked by Wall St. Rank held Elevance Health as of Q2 2024.

Based on Janiczek Wealth Management's 13F filing for Q2 2024, filed 25 Jul 2024.